test

Gregory J. Flesher Appointed President and Chief Executive Officer   SAN DIEGO, December 9, 2020 – Reneo Pharmaceuticals, Inc. today announced it raised $95 million in a Series B financing co-led by Novo Ventures and Abingworth and supported by existing investors New Enterprise Associates, RiverVest Venture Partners, Pappas Capital, and Lundbeckfonden Ventures, as well as… Continue reading Reneo Pharmaceuticals Raises $95 Million in Series B Financing, Co-led by Novo Ventures and Abingworth

A global clinical trial is slated to begin for early next year to evaluate REN001 for the treatment of primary mitochondrial myopathies (PMM), including MELAS syndrome   For LCHAD deficiency and other fatty acid oxidation disorders (FAOD), a Phase 1b clinical trial is currently recruiting and expanding globally and an international observational study is planned… Continue reading Reneo Receives Orphan Drug Designations from the EMA for REN001 for the Treatment of LCHAD Deficiency and MELAS Syndrome and Moves Forward with Clinical Trials

A small biotech company is aiming to recharge tired cells, giving mitochondrial disease patients new hope of a disease-specific treatment.   “We focus on patients, going after disease with high unmet needs, like primary mitochondrial myopathies,” Niall O’Donnell, Ph.D., President, CEO and Director of Reneo Pharmaceuticals, told BioSpace.   https://www.biospace.com/article/restoring-cellular-power-outages-a-new-drug-to-treat-mitochondrial-diseases/